Table 3.
Univariate and multi-variate models assessing uptake of an HIV test in each injecting-related cohort in all of Glasgow, 2010–June 2021
| Time period | N | HIV test in the last year (% of N) | Univariate ORa (95% CI) | P-value | Multi-variate aORa (95% CI) | P-value |
|---|---|---|---|---|---|---|
| Needle exchange surveillance initiative cohortb | ||||||
| Pre HIV outbreak (2010–2014) | 3,139 | 889 (28%) | 0.32 (0.28-0.36) | < 0.001 | 0.28 (0.25 to 0.32) | < 0.001 |
| Early HIV outbreak (2015–2016) | 886 | 341 (38%) | 0.49 (0.42–0.59) | < 0.001 | 0.47 (0.40–0.55) | < 0.001 |
| Ongoing HIV outbreak (2017–2018) | 1,802 | 1,002 (56%) | 1 | 1 | ||
| COVID-19 (2020–2021) | – | – | – | – | – | – |
| Opiate agonist therapy cohortc | ||||||
| Pre HIV outbreak (2010–2014) | 11,908 | 1,973 (17%) | 0.17 (0.16–0.18) | < 0.001 | 0.16 (0.15–0.17) | < 0.001 |
| Early HIV outbreak (2015–2016) | 9,519 | 3,430 (36%) | 0.48 (0.46–0.51) | < 0.001 | 0.47 (0.44–0.49) | < 0.001 |
| Ongoing HIV outbreak (2017–2018) | 9,412 | 5,053 (54%) | 1 | 1 | ||
| COVID-19 (2020–2021) | 7,599 | 2,847 (37%) | 0.52 (0.49–0.55) | < 0.001 | 0.50 (0.48–0.53) | < 0.001 |
| Injecting-related hospital admission cohortd | ||||||
| Pre HIV outbreak (2010–2014) | 4,826 | 737 (15%) | 0.24 (0.22–0.27) | < 0.001 | 0.19 (0.17–0.21) | < 0.001 |
| Early HIV outbreak (2015–2016) | 3,347 | 1,082 (32%) | 0.64 (0.59–0.71) | < 0.001 | 0.54 (0.49–0.60) | < 0.001 |
| Ongoing HIV outbreak (2017–2019) | 5,297 | 2,248 (42%) | 1 | 1 | ||
| COVID-19 (2020–2021) | 3,008 | 1,411 (47%) | 1.20 (1.10–1.30) | < 0.001 | 1.19 (1.08–1.31) | 0.001 |
OR odds ratio, aOR adjusted odds ratio
aMulti-level framework applied to adjust for duplicates
bAdjusted for: calendar period (excluding COVID-19 period), local authority, age, sex, prescribed methadone
cAdjusted for: calendar period, local authority, age, sex, recent drug-related hospital admission (last 2 years)
dAdjusted for: calendar period, local authority, age, sex, prescribed OAT